Skip to main content

Clinical Trials

American Society of Hematology Meeting 2014: CMRG 001

First Report of the Myeloma Canada Research Network (MCRN)-001 Trial UtilizingBortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan(BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Basedon Achievement of Minimal Residual Disease (MRD) Negativity

View

American Society of Hematology Meeting 2015: CMRG 001

Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite chain (HLC) Normalization

View

International Myeloma Workshop Meeting 2015: CMRG 001

Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)

View

American Society of Hematology Meeting 2016: CMRG 002

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

View

American Society of Hematology Meeting 2016: CMRG 001

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan(BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated ResultsIncluding Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain(HLC) Ratio Assessments

View

American Society of Hematology Meeting 2018: CMRG 003

A single arm phase II study of high-dose weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 prior therapies

View

American Society of Hematology Meeting 2019: CMRG 004

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

View

American Society of Hematology Meeting 2020: CMRG 004

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

View

International Myeloma Workshop 2019: CMRG 007

The ALGONQUIN Study: A Phase 1/2 Multi-Center, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination with Pomalidomide and Low Dose Dexamethasone in Subjects with RRMM

View

European Hematology Association Congress 2020: CMRG 007

Phase 1/2 Study of Belantamab mafodotin in Combination with Pomalidomide and Dexamethasone: Results for Part 1 Dose Finding

View

American Society of Hematology Meeting 2020: CMRG 007

Part 1 Results of a Dose Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

View

International Myeloma Workshop 2021: CMRG 007

Extended Follow-Up Safety and Efficacy Results of Belantamab Mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg Combined with Pom and Dex for the Treatment of Relapsed/Refractory Multiple Myeloma

View

International Myeloma Workshop 2019: CMRG 009

Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM)

View

Real-World Evidence

European Hematology Association Meeting 2018

The Myeloma Canada Research Network Canadian Multiple Myeloma Database (MCRN CMM-DB): Multi-Institutional Sharing Of Clinical Data For Research

View

American Society of Hematology Meeting 2018

Real-world outcomes with bortezomib-containing regimens and lenalidomide and dexamethasone for the treatment of transplant ineligible MM patients: A multi-institutional report from the National Myeloma Canada Research Network (MCRN) database

View

European Journal of Hematology Vol. 105 Issue 5: May 2021

The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma

View

Haematologica Vol. 106 No. 6: June, 2021

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database

View

Journal of Cancer Immunology Vol. 3 Issue 1: 2021

Lenalidomide Maintenance After Autologous Stem Cell Transplant: The Utility of Real-World Data and Future Areas of Study

View

British Journal of Haematology Vol. 193 Issue 3: May 2021

Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database

View

European Hematology Association Meeting 2019

Lenalidomide maintenance positively impacts outcomes in multiple myeloma without negative impacts in relapse: An analysis of Real World Data from the Myeloma Canada Research Network National Database

View

International Myeloma Workshop 2019

The impact of lenalidomide maintenance on second line chemotherapy in transplant eligible patients with multiple myeloma in the Canadian setting

View

American Society of Hematology Meeting 2019

Treatment of myeloma patients progressing on lenalidomide-based maintenance after ASCT performed as part of 1st, 2nd or 3rd line therapy: Real-World results from the National Myeloma Canada Research Network Database

View

European Hematology Association Meeting 2019

Treatment of multiple myeloma patients progressing on lenalidomide-based regimens

View

American Society of Hematology Meeting 2020

Efficacy of daratumumab containing regimens post lenalidomide maintenance in transplant eligible patients: Real-World Experience from the Canadian Myeloma Research Group Database

View

American Society of Hematology Meeting 2020

Sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

View

American Society of Hematology Meeting 2020

Maintenance therapy but not tandem autologous stem cell transplant (ASCT) improves outcomes in multiple myeloma with high-risk cytogenetics: Results from the Canadian Myeloma Research Group (CMRG) Database

View

American Society of Hematology Meeting 2020

Efficacy of daratumumab containing regimens post lenalidomide maintenance in transplant eligible patients: Real-World Experience from the Canadian Myeloma Research Group Database

View

American Society of Hematology Meeting 2020

Sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

View

European Hematology Association Meeting 2021

Carfilzomib-containing regimens for relapsed multiple myeloma in a Real-World setting: A multi-institutional report from the Canadian Myeloma Research Group (CMRG)

View

European Hematology Association Meeting 2021

Survival and outcomes of newly-diagnosed multiple myeloma patients stratified by transplant status diagnosed between 2007-2018: Real-World analysis from the Canadian Myeloma Research Group Database

View

European Hematology Association Meeting 2021

Outcomes of daratumumab-containing regimens in the treatment of relapsed multiple myeloma: Real-World data from the Canadian Myeloma Research Group Database

View

European Journal of Haematology Vol. 107 Issue 4: October 2021

Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada

View